Pier Capital, LLC Mirati Therapeutics, Inc. Transaction History

Pier Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$132.01 - $190.29 $8.06 Million - $11.6 Million	-61,065 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$132.13 - $177.45 $288,836 - $387,905	-2,186 Reduced 3.46%	61,065 $10.8 Million
Q2 2021 Aug 12, 2021	BUY	$144.0 - $179.73 $2.74 Million - $3.42 Million	19,033 Added 43.04%	63,251 $10.2 Million
Q1 2021 May 13, 2021	BUY	$158.92 - $221.61 $2.72 Million - $3.8 Million	17,128 Added 63.23%	44,218 $7.58 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $136,932 - $203,028	845 Added 3.22%	27,090 $5.95 Million
Q3 2020 Nov 13, 2020	SELL	$113.26 - $167.27 $4.93 Million - $7.28 Million	-43,521 Reduced 62.38%	26,245 $4.36 Million
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $539,642 - $902,202	7,494 Added 12.03%	69,766 $7.97 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $4.35 Million - $7.24 Million	62,272 New	62,272 $4.79 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pier Capital, LLC with notifications on news.